CClinicalTrials.gg
Not yet recruitingNCT06989502COHESION-IUpdated May 25, 2025

Implementation of the COmmunity HEalth System InnovatiON Project in Low- and Middle- Income Countries

An interventional study of Co-creation (2016 to 2019) + Co-design (2023 to 2024) and Co-design only (2023 to 2024) in Hypertension, Diabetes Mellitus and Neglected Tropical Diseases, sponsored by Universidad Peruana Cayetano Heredia. Not yet recruiting at 3 sites in 3 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-25.

Sponsored by Universidad Peruana Cayetano Heredia · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
2,094
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The COHESION-I project will evaluate the effects of the co-creation intervention (2016 to 2019) and the co-design intervention (2023 to 2024) on improving (a) health system responsiveness, and (b) patient satisfaction, at the primary health care level, in Peru, Nepal and Mozambique, in relation to chronic diseases (hypertension, and diabetes mellitus), as well as specific neglected tropical diseases. Each intervention has been tailored to the context and characteristics of each one of the aforementioned low- and middle-income countries.

For this quasi-experimental study, three arms were established: the co-creation (2016 to 2019) + co-design (2023 to 2024) arm; the co-design only (2023 to 2024) arm; and the control group (no intervention; usual care). The evaluation will be composed of four types of evaluations: quantitative; qualitative; economic; and process evaluation

Read the detailed description

The COHESION-I project (I is for Intervention) has two main objectives: first, to implement and evaluate the context specific co-created interventions in the three countries - Mozambique, Nepal, and Peru (Component 1), and second, to explore the possibilities to transfer the experience and lessons learnt to other countries (India) for adaptation of such intervention approach in a different context (Component 2). COHESION-I continues and is based on a previous project called COHESION. The previous project, The COmmunity HEalth System InnovatiON (COHESION) project was a 4-year project that started in 2016 as a collaboration between research teams from Mozambique, Nepal, Peru and Switzerland. It enabled formative research to be conducted at policy, health system and community levels using tracer chronic conditions that included non-communicable diseases (NCDs) (diabetes and hypertension), and a specific neglected tropical disease (NTDs) (Schistosomiasis in Mozambique, Leprosy in Nepal and Epilepsy resulting from neurocysticercosis in Peru). The results from this formative research were utilised as part of a process for identifying adequate interventions through a participatory approach with communities, primary healthcare (PHC) workers, and regional health authorities. Meetings with different stakeholders were carried out between 2017 and 2018 to propose context- relevant interventions oriented to address the challenges of providing care for people affected by NCDs and NTDs. During the meetings, participants provided feedback regarding problems and potential solutions for chronic care and health services in general and proposed possible areas of intervention. Upon completion of all the meetings, each country identified the main components to be included in their interventions that were focussed on communities, healthcare workers and facilities. For example, the suggested intervention components in Mozambique include: (i) radio programs, spots, or podcasts and pamphlets to inform population about hypertension, (ii) development of facility-based guideline/algorithm, training in hypertension and clear communication, and group discussions on challenges and opportunities to manage chronic diseases, and (iii) establishment of a medical appointment system for people with chronic diseases.

In this new phase, the COHESION-I project, which will be conducted from 2022 to 2026, the impact of a co-creation/co-design strategy will be evaluated in terms of two main outcomes: on the one hand, improved health system responsiveness at primary care level and patient satisfaction and, on the other hand, improved health care for chronic diseases. The general research objective of COHESION-I is to implement and evaluate at the primary health care level the co-created/co-designed interventions in the selected settings in each of the three countries (Mozambique, Nepal and Peru), focusing on Non-Communicable Diseases (diabetes, hypertension) and Neglected Tropical Diseases (schistosomiasis in Mozambique, Leprosy in Nepal and neurocysticercosis in Peru). This study involves the following evaluation components: quantitative evaluation, qualitative evaluation, economic evaluation, and process evaluation. There will be five trimesters in total for undertaking these different types of evaluations.

This study will implement a mixed-methods approach that includes a pre-post quasi-experimental study: a quantitative component that will accrue an initial survey and five repeated measurements over time with an embedded qualitative study.The study will be developed in three low- and middle-income countries: Mozambique, Nepal and Peru. In each country, the COHESION-I project will be implemented in six sites (A, B, C, D, E and F). From these six sites, two of them have already been selected (A and B sites). The A and B sites are the ones where the co-creation process was conducted between 2016 - 2019, and now, during the current phase, receive the co-designed intervention (co-created + co-designed). Sites C and D have been selected and they have similar characteristics as sites A and B. The difference is that in the previous phase of the COHESION project did not hold any previous activity in these settings. Participants in sites C and D are being engaged for the first time and will receive the same co-designed intervention as sites A and B, but without having been involved in the co-creation process (2016 to 2019). Finally, sites E and F, will share similar characteristics as sites A, B, C, and D, but they will receive no intervention (control sites or usual care).

02

Conditions studied

  • Hypertension
  • Diabetes Mellitus
  • Neglected Tropical Diseases

Keywords

  • Hypertension
  • Diabetes Mellitus
  • Neglected Tropical Diseases
  • Chronic Disease
  • Primary Health Care
  • Implementation Science
  • Low and Middle Income Countries
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria for PHC users with diabetes, hypertension, and/or NTDs:

  • Males or females aged 18 years and over, from the selected sites
  • Having used the health services in the previous three months
  • Diagnosis (or estimated risk) of diabetes mellitus type 2, hypertension, or neurocysticercosis
  • Must be able to listen to radio programs, or other audio material

Inclusion Criteria for PHC users without diabetes, hypertension, and/or NTDs:

  • Males or females aged 18 years and over, from the selected sites
  • Having used the health services in the previous three months
  • Must be able to listen to radio programs, or other audio material

Exclusion Criteria for PHC users without diabetes, hypertension, and/or NTDs:

  • Diagnosis (or estimated risk) of diabetes mellitus type 2, hypertension, or neurocysticercosis

The criteria mentioned above refer solely to the quantitative evaluation. For the other types of evaluation, some different populations will be included (such as healthcare workers, local authorities and other stakeholders).

04

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
2,094 participants (estimated)

Study arms

  • Experimental
    Co-creation (2016 to 2019) + Co-design (2023 to 2024)

    PERU: * Radio programs with content related to health care * Capacity building on management of diabetes, hypertension and neurocysticercosis * Communication jar to prompt communication between health workers and patients * Decentralized decision-making on facility improvement NEPAL: * Radio and pamphlets to promote Primary Health Care (PHC) * Involvement of Female Community Health Volunteers * Capacity building on management of diabetes, hypertension and lepra * Flip charts, guidelines and posters for management of diseases and to prompt communication between health workers and patients * Decentralized decision-making on facility improvement MOZAMBIQUE: * Radio and pamphlets informing population on hypertension, PHC and appointment system * Facility based guideline/algorithm * Capacity building on hypertension, diabetes and schistosomiasis * Establishment of an "information booth" * Group discussions on challenges and opportunities * Advocacy on the issue of access to medicines

    Behavioral: Co-creation (2016 to 2019) + Co-design (2023 to 2024)

  • Experimental
    Co-design only (2023 to 2024)

    PERU: * Radio programs with content related to health care * Capacity building on management of diabetes, hypertension and neurocysticercosis * Communication jar to prompt communication between health workers and patients * Decentralized decision-making on facility improvement NEPAL: * Radio and pamphlets to promote Primary Health Care (PHC) * Involvement of Female Community Health Volunteers * Capacity building on management of diabetes, hypertension and lepra * Flip charts, guidelines and posters for management of diseases and to prompt communication between health workers and patients * Decentralized decision-making on facility improvement MOZAMBIQUE: * Radio and pamphlets informing population on hypertension, PHC and appointment system * Facility based guideline/algorithm * Capacity building on hypertension, diabetes and schistosomiasis * Establishment of an "information booth" * Group discussions on challenges and opportunities * Advocacy on the issue of access to medicines

    Behavioral: Co-design only (2023 to 2024)

  • No intervention
    Control

    Usual care, understood as the Primary Health Care (PHC) that the target patient population receives as part of the conventional or usual medical practice in each of their communities, in Peru, Nepal, and Mozambique

Interventions

  • BehavioralCo-creation (2016 to 2019) + Co-design (2023 to 2024)

    It includes interventions implemented in a sequential way: a) The co-creation intervention (between 2016 and 2019), and b) the co-design intervention (between 2023 and 2024). In this group of sequential interventions, relevant stakeholders have already been engaged in the project and they would be familiar with the intervention components. Their participation this time will enable updating and refining the previous co-creation intervention through the co-design process. The intervention will encompass activities with the health service users and healthcare workers, in Peru, Nepal, and Mozambique

  • BehavioralCo-design only (2023 to 2024)

    The same intervention activities of the first group (between 2023 and 2024), but without having them involved in the previous co-creation process. In consequence, relevant stakeholders in the corresponding sites are not expected to be as engaged in the project (in contrast to the intervention that includes co-creation), and they would not be very familiar with the intervention components of COHESION-I. As in the first group, the intervention will encompass activities with the health service users and healthcare workers, in Peru, Nepal, and Mozambique

05

What researchers measure

Primary outcomes

  1. Patient Satisfaction (PS)

    Score derived from the Short-Form Patient Satisfaction Questionnaire (PSQ-18), which has been adapted in the local languages of Peru, Nepal, and Mozambique, from its original source in English. The questionnaire consists of 18 items, with classic Likert scale format (5 alternatives). The number of dimensions of Patient Satisfaction could vary by country, as literature demonstrates

    Time frame: Month 1 (baseline), Month 5 (pre-intervention), Month 9 (pre-intervention), Month 13 (during intervention), Month 17 (post-intervention), Month 21 (follow-up)

  2. Health System Responsiveness (HSR)

    Score derived from the World Health Organization Health System Responsiveness World Survey, including five -of the eight established- dimensions: autonomy, dignity, clear communication, choice of healthcare provider, and confidentiality. The questionnaire has been adapted in the local languages of Peru, Nepal, and Mozambique, from its original source in English; and it consists of 18 items, with diverse response alternatives (e.g. frequency, "yes or no", amongst other formats)

    Time frame: Month 1 (baseline), Month 9 (pre-intervention), Month 13 (during intervention), Month 17 (post-intervention)

  3. Quality of Life (QoL)

    Score derived from the 5-level EQ-5D version questionnaire (EQ-5D-5L), which consists of 2 components. The first one is the EQ-5D descriptive system, which comprises five theoretical dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The second component is the EQ visual analogue scale (EQ VAS), which records the patient's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'The best health you can image' (score = 100), and 'The worst health you can image' (score = 0). The EQ-5D-5L official translations for Spanish, Nepali, and Portuguese will be used

    Time frame: Month 1 (baseline), Month 9 (pre-intervention), Month 21 (follow-up)

Secondary outcomes

  1. Quantitative evaluation

    A group of outcomes, incluiding: access to antihypertensive drugs; antihypertensive treatment; blood pressure control; access to antidiabetic drugs; antidiabetic treatment; glycemic control. The evaluation of these outcomes, using quantitative methods, will be carried out through: questionnaires, adapted in the local languages of Peru, Nepal, and Mozambique

    Time frame: Month 1 (baseline), Month 5 (pre-intervention), Month 9 (pre-intervention), Month 13 (during intervention), Month 17 (post-intervention), Month 21 (follow-up)

  2. Qualitative evaluation

    A group of outcomes, incluiding: perceived value of health services; patient satisfaction; perceived roles and responsibilities of healthcare workers; perceived capacity of healthcare workers to deliver services. The evaluation of these outcomes, using qualitative methods, will be carried out through: semi-structured interviews, pictures taken by participants, individual diaries and team meetings (research team reflexivity)

    Time frame: Month 1 (baseline), Month 8 (pre-intervention), Month 14 (during intervention), Month 20 (post-intervention)

  3. Economic evaluation 1

    A group of outcomes, incluiding: cost per satisfied patient; cost per patient with a positive perception of health system's responsiveness; out-of-pocket expenses; cost per QALY gained. The evaluation of these outcomes, using mixed methods, will be carried out through: interviews of key informants, on-site observations, and review of documentation

    Time frame: Month 5 (pre-intervention), Month 21 (follow-up)

  4. Economic evaluation 2

    Cost of services provided

    Time frame: Month 9 (pre-intervention), Month 13 (during intervention), Month 17 (post-intervention), Month 21 (follow-up)

  5. Process evaluation: Context (part 1)

    Health system-level indicators

    Time frame: Month 5 (pre-intervention), Month 21 (follow-up)

  6. Process evaluation: Context (part 2)

    Barriers and facilitators

    Time frame: Month 5 (pre-intervention), Month 13 (during intervention), Month 21 (follow-up)

  7. Mechanism of Impact

    Coherence, Cognitive Participation, Collective Action and Reflexing Monitoring

    Time frame: Month 5 (pre-intervention), Month 13 (during intervention), Month 21 (follow-up)

  8. Implementation outcomes (part 1)

    Reach and dose of the communication strategy

    Time frame: Month 5 (pre-intervention), Month 13 (during intervention), Month 21 (follow-up)

  9. Implementation outcomes (part 2)

    Acceptability of the training of the HCWs

    Time frame: Month 13 (during intervention)

06

Study locations

3 sites
  • Eduardo Mondlane University
    Maputo, Mozambique
    • Albertino Damasceno, MD, PhD · Contact
  • B.P. Koirala Institute of Health Sciences
    Dharān Bāzār, Nepal
    • Sanjib Sharma, MD · Contact
  • Universidad Peruana Cayetano Heredia
    Piura, Peru
    • María Lazo-Porras, MD, MSc, PhD · Contact
    • Antonio Bernabe-Ortiz, MD, MPH, PhD · Contact
07

References and documents

Publications

  • Beran D, Lazo-Porras M, Cardenas MK, Chappuis F, Damasceno A, Jha N, Madede T, Lachat S, Perez Leon S, Aya Pastrana N, Pesantes MA, Singh SB, Sharma S, Somerville C, Suggs LS, Miranda JJ. Moving from formative research to co-creation of interventions: insights from a community health system project in Mozambique, Nepal and Peru. BMJ Glob Health. 2018 Nov 16;3(6):e001183. doi: 10.1136/bmjgh-2018-001183. eCollection 2018. PubMed 30498592 ↗
  • Pesantes MA, Somerville C, Singh SB, Perez-Leon S, Madede T, Suggs S, Beran D. Disruption, changes, and adaptation: Experiences with chronic conditions in Mozambique, Nepal and Peru. Glob Public Health. 2020 Mar;15(3):372-383. doi: 10.1080/17441692.2019.1668453. Epub 2019 Oct 9. PubMed 31596656 ↗
  • Cardenas MK, Perez-Leon S, Singh SB, Madede T, Munguambe S, Govo V, Jha N, Damasceno A, Miranda JJ, Beran D. Forty years after Alma-Ata: primary health-care preparedness for chronic diseases in Mozambique, Nepal and Peru. Glob Health Action. 2021 Jan 1;14(1):1975920. doi: 10.1080/16549716.2021.1975920. PubMed 34569443 ↗
  • Bernabe-Ortiz A, Perel P, Miranda JJ, Smeeth L. Diagnostic accuracy of the Finnish Diabetes Risk Score (FINDRISC) for undiagnosed T2DM in Peruvian population. Prim Care Diabetes. 2018 Dec;12(6):517-525. doi: 10.1016/j.pcd.2018.07.015. Epub 2018 Aug 18. PubMed 30131300 ↗

Individual participant data

Plan to share: Undecided

08

Registry details

Key details

Study ID
NCT06989502
Lead sponsor
Universidad Peruana Cayetano Heredia
Collaborators
Eduardo Mondlane University, B.P. Koirala Institute of Health Sciences
Responsible party
María Lazo Porras (Research Associate at CRONICAS, Universidad Peruana Cayetano Heredia) — Principal investigator
First posted
May 25, 2025
Start date
May 17, 2025 (estimated)
Primary completion
Oct 31, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
May 25, 2025

Study contacts

María Lazo-Porras, MD, MSc, PhD
Contact
maria.lazo@upch.pe
511-2416978
Antonio Bernabe-Ortiz, MD, MPH, PhD
Contact
antonio.bernabe@upch.pe
María Lazo-Porras, MD, MSc, PhD
principal investigator · Universidad Peruana Cayetano Heredia

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion